Literature DB >> 16704711

Magnetic resonance imaging determination of extraocular eye muscle volume in patients with thyroid-associated ophthalmopathy and proptosis.

Jan Kvetny1, Katriina Bøcker Puhakka, Lisbeth Røhl.   

Abstract

PURPOSE: Recent studies concerning the association between extraocular muscle (EOM) enlargement in thyroid-associated ophthalmopathy (TAO) and immunological and clinical activity have not been conclusive, probably due to a lack of uniform imaging methods (ultrasonography, computer tomography [CT] or magnetic resonance imaging [MRI]) and difficulties in the determination of EOM volume. The aim of the present study was to examine the significance of EOM enlargement as established by MRI-based volume determination, with reference to proptosis and the presence of autoantibodies, clinical activity and the duration of active disease.
METHODS: We determined EOM volume using MRI in 15 patients concomitantly with the determination of TSH, thyroid hormones, thyrotropin receptor antibodies (TRab) thyroid peroxidase antibodies (TPOab) and clinical activity score (CAS) at entry. We also established the duration until cessation of clinically active TAO.
RESULTS: All 15 patients had bilateral EOM enlargement, but swelling of orbital fatty tissue was absent. Significant correlations between thickness of musculi rectales and proptosis, values of TRab, CAS, and duration of activity were observed.
CONCLUSION: Our results support the hypothesis of a role of thyrotropin receptor antibodies in the pathogenesis of TAO and suggest that only EOM enlargement is responsible for proptosis in TAO.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16704711     DOI: 10.1111/j.1600-0420.2005.00617.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  8 in total

1.  Usefulness of the ratio of orbital fat to total orbit area in mild-to-moderate thyroid-associated ophthalmopathy.

Authors:  H C Kim; S W Yoon; H Lew
Journal:  Br J Radiol       Date:  2015-07-07       Impact factor: 3.039

2.  Enhanced-depth optical coherence tomography for imaging horizontal rectus muscles in Graves' orbitopathy.

Authors:  Nathanael U Häner; Muriel Dysli; Mathias Abegg; Martin S Zinkernagel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-07       Impact factor: 3.117

3.  Quantitative analysis of orbital soft tissues on computed tomography to assess the activity of thyroid-associated orbitopathy.

Authors:  Jun Soo Byun; Nam Ju Moon; Jeong Kyu Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-11-12       Impact factor: 3.117

4.  Graves' ophthalmopathy: the role of diffusion-weighted imaging in detecting involvement of extraocular muscles in early period of disease.

Authors:  R Kilicarslan; A Alkan; M M Ilhan; H Yetis; A Aralasmak; E Tasan
Journal:  Br J Radiol       Date:  2014-12-19       Impact factor: 3.039

5.  Orbital Fat Volumetry and Water Fraction Measurements Using T2-Weighted FSE-IDEAL Imaging in Patients with Thyroid-Associated Orbitopathy.

Authors:  Y Kaichi; K Tanitame; H Itakura; H Ohno; M Yoneda; Y Takahashi; Y Akiyama; K Awai
Journal:  AJNR Am J Neuroradiol       Date:  2016-06-30       Impact factor: 3.825

6.  A musculoskeletal model of low grade connective tissue inflammation in patients with thyroid associated ophthalmopathy (TAO): the WOMED concept of lateral tension and its general implications in disease.

Authors:  Roy Moncayo; Helga Moncayo
Journal:  BMC Musculoskelet Disord       Date:  2007-02-23       Impact factor: 2.362

7.  Thyroid-associated Orbitopathy: Quantitative Evaluation of the Orbital Fat Volume and Edema Using IDEAL-FSE.

Authors:  Yoko Kaichi; Keizo Tanitame; Hiroaki Terada; Hideki Itakura; Haruya Ohno; Masayasu Yoneda; Yuji Takahashi; Yuji Akiyama; Kazuo Awai
Journal:  Eur J Radiol Open       Date:  2019-05-18

8.  Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy.

Authors:  Tomoaki Higashiyama; Yasuhiro Nishida; Masahito Ohji
Journal:  Clin Ophthalmol       Date:  2016-04-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.